B

Brainstorm Cell Therapeutics
D

BCLI

2.13000
USD
-0.17
(-7.39%)
مغلق
حجم التداول
1,379
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
12,148,297
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    APLS
    0.290
    (0.96%)
    30.390 USD
    A
    ASND
    -4.910
    (-3.75%)
    126.150 USD
    A
    ATHA
    0.00810
    (1.52%)
    0.54010 USD
    M
    MBIO
    -0.14000
    (-3.29%)
    4.12000 USD
    M
    MDB
    2.86
    (1.11%)
    260.72 USD
    Q
    QURE
    0.390
    (2.61%)
    15.310 USD
    R
    RYTM
    -0.210
    (-0.37%)
    57.270 USD
    V
    VYGR
    0.22000
    (4.21%)
    5.45000 USD
    المزيد
الأخبار
المقالات

العنوان: Brainstorm Cell Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.